


# PRODUCT INFORMATION



## Filgotinib

Item No. 17669

**CAS Registry No.:** 1206161-97-8  
**Formal Name:** N-[5-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxamide  
**Synonym:** GLPG0634  
**MF:** C<sub>21</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S  
**FW:** 425.5  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 233, 300 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Filgotinib is supplied as a crystalline solid. A stock solution may be made by dissolving the filgotinib in the solvent of choice. Filgotinib is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of filgotinib in these solvents is approximately 15 mg/ml.

For maximum solubility in aqueous buffers, filgotinib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Filgotinib has a solubility of approximately 0.15 mg/ml in a 1:5 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Filgotinib is a JAK1 inhibitor (IC<sub>50</sub> = 10 nM).<sup>1</sup> It is selective for JAK1 over JAK3 (IC<sub>50</sub> = 810 nM) but also inhibits JAK2 and tyrosine kinase 2 (Tyk2; IC<sub>50</sub>s = 28 and 116 nM, respectively), as well as Abl, FLT1, -3, and -4, FMS, Mer, and TBK1 activity by greater than 35% in a panel of 177 tyrosine kinases at 1 μM. Filgotinib inhibits IL-6-induced phosphorylation of STAT1 in CD4<sup>+</sup> T cells with an IC<sub>50</sub> value of 629 nM in isolated human whole blood. It reduces hind paw macrophage and T cell infiltration and bone erosion in a rat model of collagen-induced arthritis when administered at doses ranging from 0.1 to 30 mg/kg per day for 15 days.

### Reference

1. Van Rompaey, L., Galien, R., van der Aar, E.M., *et al.* Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. *J. Immunol.* **191**(7), 3568-3577 (2013).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/07/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM